AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

ArriVent BioPharma, Inc. ( (AVBP) ) has released its Q3 earnings. Here is a breakdown of the information ArriVent BioPharma, Inc. presented to ...

Male sex was also shown to be an independent risk factor for longer hospital stays and increased hospitalization costs at ...

The EGFR mutation is particularly common in NSCLC patients of Asian heritage. In China, where approximately 693,000 patients are diagnosed with NSCLC annually, approximately 50 percent of diagnoses ...

Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer ...

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...

Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...